Canadian guidelines state mammography is not needed before 50 years

Share this article:

New recommendations from the Canadian Task Force on Preventive Health Care advise against routine mammography screening for women aged 40 to 49 years and extend the screening interval from the current clinical practice of every 2 years for women aged 50 to 74 years to every 2 to 3 years (CMAJ. 2011;183[17]:1991-2001; www.cmaj.ca/content/183/17/1991.full.pdf+html). The guideline, which updates recommendations issued in 2001, are intended for application in average-risk women in their 40s, 50s, and 70s who have not had breast cancer and do not have a mother, sister, or daughter with a history of the disease.

The independent body of 14 primary-care and prevention experts concluded that the latest scientific evidence in breast cancer screening does not show that screening with mammography reduces the risk of all-cause mortality.  In addition, they found that although screening might permit surgery for breast cancer at an earlier stage than diagnosis of clinically evident cancer—thus permitting the use of less invasive procedures for some women—available trial data suggest that the overall risk of mastectomy is significantly increased among recipients of screening compared with women who have not undergone screening.

The task force makes the following key recommendations:

  • Women aged 40 to 49 years should not undergo routine mammography because the risk of cancer is low in this group and the risks of false-positive results, overdiagnosis, and overtreatment are higher.
  • Women aged 50 to 69 years should undergo routine screening with mammography every 2 to 3 years. A greater reduction in mortality is seen with mammography for women in this age group who are at average risk for breast cancer compared with similar women aged 40 to 49 years.
  • Women aged 70 to 74 years should undergo routine screening with mammography every 2 to 3 years.
  • Average-risk women should not undergo screening with magnetic resonance imaging (MRI), as there is no evidence that MRI screening reduces the risk of mortality or other clinically relevant adverse outcomes.
  • For the same reason that MRI screening is not recommended, clinicians should not perform routine clinical breast examinations, nor should women perform breast self-examinations, to screen for breast cancer.
  • When deciding whether to recommend mammography to a specific patient, clinicians should first discuss the tradeoff between benefits and harms as well as the patient's values and preferences.      

Overall, notes the task force, the reduction in mortality associated with screening mammography is relatively small for women aged 40 to 79 years at average risk of breast cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Protein deletion predicts length of progression free survival (PFS) in patients with ...

Deletion of the Bcl-2-like protein 11 (BIM) in advanced non-small cell lung cancer has been associated with shorter progression free survival (PFS).

Risk of premature menopause after Hodgkin lymphoma treatment is mapped

Women treated for Hodgkin lymphoma will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments.

Patient and tumor characteristics in melanoma examined for clues to aggressive form ...

Researchers in Australia examined patient and tumor characteristics of melanomas for higher mitotic rates (a marker of tumor cell growth) in an effort to increase early detection.